Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Parkinson's Disease

Free Subscription 01.07.2024 3 BMC Neurol 2 J Neural Transm (Vienna) 1 J Neurochem 11 Mov Disord 1 Nat Rev Neurosci 1 Neurobiol Dis 1 Proc Natl Acad Sci U S A 1 Rev Neurol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Neurol

1. WATTENBACH C, Ellrichmann G, Feinkohl I, Voss S, et al
   Incidence of Parkinson's disease in Germany based on prevalence data from 70 million patients of the statutory health insurance.
   BMC Neurol. 2024;24:221.
   PubMed         Abstract available
   
   
2. VAN DER HEIDE A, Goltz F, de Vries NM, Bloem BR, et al
   Study protocol for the MIND-PD study: a randomized controlled trial to investigate clinical and biological effects of mindfulness-based cognitive therapy in people with Parkinson's disease.
   BMC Neurol. 2024;24:219.
   PubMed         Abstract available
   
   
3. JANSSEN DAALEN JM, Meinders MJ, Mathur S, van Hees HWH, et al
   Randomized controlled trial of intermittent hypoxia in Parkinson's disease: study rationale and protocol.
   BMC Neurol. 2024;24:212.
   PubMed         Abstract available
   
   

   
   J Neural Transm (Vienna)

4. HOGLINGER GU, Lang AE
   The why and how of the SynNerGe criteria of Parkinson s disease.
   J Neural Transm (Vienna). 2024 Jun 25. doi: 10.1007/s00702-024-02797.
   PubMed         Abstract available
   
   
5. FABBRI M, Rousseau V, Corvol JC, Sommet A, et al
   Amantadine use in the French prospective NS-Park cohort.
   J Neural Transm (Vienna). 2024;131:799-811.
   PubMed         Abstract available
   
   

   
   J Neurochem

6. ALVES BDS, Schimith LE, da Cunha AB, Dora CL, et al
   Omega-3 polyunsaturated fatty acids and Parkinson's disease: A systematic review of animal studies.
   J Neurochem. 2024 Jun 24. doi: 10.1111/jnc.16154.
   PubMed         Abstract available
   
   

   
   Mov Disord

7. AVENALI M, Cerri S, Palmieri I, Ongari G, et al
   Functional Study of SNCA p.V15A Variant: Further Linking alpha-Synuclein and Glucocerebrosidase.
   Mov Disord. 2024;39:1060-1065.
   PubMed         Abstract available
   
   
8. SIMONET C, Perez-Carbonell L, Galmes-Ordinas MA, Huxford BFR, et al
   The Motor Dysfunction Seen in Isolated REM Sleep Behavior Disorder.
   Mov Disord. 2024;39:1054-1059.
   PubMed         Abstract available
   
   
9. BUUR L, Wiedemann J, Larsen F, Ben Alaya-Fourati F, et al
   Randomized Phase I Trial of the alpha-Synuclein Antibody Lu AF82422.
   Mov Disord. 2024;39:936-944.
   PubMed         Abstract available
   
   
10. OLANOW CW, McIntyre D, Matarazzo M, Leinonen M, et al
    Continuous Levodopa Delivery with an Intraoral Micropump System: An Open-Label Pharmacokinetics and Clinical Study.
    Mov Disord. 2024;39:945-954.
    PubMed         Abstract available
    
    
11. SCHNEIDER RB, Mills KA, Nirenberg MJ, Dobkin RD, et al
    Defining the Importance of Minor Hallucinations in Parkinson's Disease.
    Mov Disord. 2024;39:1083.
    PubMed        
    
    
12. OUTEIRO TF, Antonini A, Ferreira JJ
    Reply to: "Rethinking Parkinson's Disease: A Syndromic Perspective".
    Mov Disord. 2024;39:1080-1081.
    PubMed        
    
    
13. LEODORI G, Mancuso M, Marchet F, Belvisi D, et al
    The Role of the Motor Cortex in the Parkinsonian Tremor Network: Is it Time for an Upgrade?
    Mov Disord. 2024;39:1084.
    PubMed        
    
    
14. KORCZYN AD
    Rethinking Parkinson's Disease: A Syndromic Perspective.
    Mov Disord. 2024;39:1079-1080.
    PubMed        
    
    
15. LEODORI G, De Bartolo MI, Piervincenzi C, Mancuso M, et al
    Mapping Motor Cortical Network Excitability and Connectivity Changes in De Novo Parkinson's Disease.
    Mov Disord. 2024 Jun 24. doi: 10.1002/mds.29901.
    PubMed         Abstract available
    
    
16. FABBRI M, Rascol O, Foltynie T, Carroll C, et al
    Advantages and Challenges of Platform Trials for Disease Modifying Therapies in Parkinson's Disease.
    Mov Disord. 2024 Jun 26. doi: 10.1002/mds.29899.
    PubMed         Abstract available
    
    
17. AKCIMEN F, van Midden V, Akerman SC, Makarious MB, et al
    Investigating the Protective Role of the Mitochondrial 2158 T > C Variant in Parkinson's Disease.
    Mov Disord. 2024 Jun 28. doi: 10.1002/mds.29892.
    PubMed        
    
    

    
    Nat Rev Neurosci

18. WILLIAMS D
    Why so slow? Models of parkinsonian bradykinesia.
    Nat Rev Neurosci. 2024 Jun 27. doi: 10.1038/s41583-024-00830.
    PubMed         Abstract available
    
    

    
    Neurobiol Dis

19. LI X, Pang H, Bu S, Zhao M, et al
    Stage-dependent differential impact of network communication on cognitive function across the continuum of cognitive decline in Parkinson's disease.
    Neurobiol Dis. 2024 Jun 24:106578. doi: 10.1016/j.nbd.2024.106578.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

20. 
    Correction for Ahuja et al., Bach1 derepression is neuroprotective in a mouse model of Parkinson's disease.
    Proc Natl Acad Sci U S A. 2024;121:e2411303121.
    PubMed        
    
    

    
    Rev Neurol

21. MARTINEZ-CASTRILLO JC, Parees-Moreno I, Lopez Sendon-Moreno JL, Perez-Torre P, et al
    [Inhaled levodopa: from evidence to experience].
    Rev Neurol. 2024;78.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Parkinson's Disease is free of charge.